Mehdi Zain, Majeethia Heli, Dwarampudi Jagan M R, Dhanda Aatin K, Gajula Meher, Goehring Lexi, Khan Faizaan, Dongre Roshan, Wu Franklin, Hu Renjie, Yim Michael T, Takashima Masayoshi, Ahmed Omar G
Department of Otolaryngology-Head and Neck Surgery, Houston Methodist Hospital Houston Texas USA.
Department of Information Science Technology, Cullen College of Engineering University of Houston Houston Texas USA.
Laryngoscope Investig Otolaryngol. 2025 Oct 7;10(5):e70261. doi: 10.1002/lio2.70261. eCollection 2025 Oct.
With growing cannabis use in the US, it is crucial to understand the impact of recreational use on sinonasal diseases like chronic rhinosinusitis (CRS), allergic rhinitis (AR), and chronic rhinitis (CR).
This cross-sectional study leveraged the NIH AllOfUs database to query patient surveys assessing cannabis usage frequency (lifetime never, monthly, weekly, or daily within the past 3 months) and consumption route (smoking or non-smoking). Cannabis users were matched to never users for demographics, healthcare visit frequency, and insurance. A stringent logistic regression model calculated odds ratios (OR) of developing AR, CRS, or CR after survey completion. Cox regression hazard ratios (HR) compared consumption routes.
Twenty-five thousand one hundred sixty-four cannabis users were matched with 113,418 never users. Users demonstrated significantly lower odds of AR, CRS, and CR than never users. For CRS, the ORs compared to never users are as follows: daily users 0.64 (95% CI 0.53-0.78), weekly users 0.61 (95% CI 0.48-0.77), and monthly users 0.80. For AR, the ORs were 0.64 (95% CI 0.58-0.71) for daily users, 0.62 (95% CI 0.54-0.71) for weekly users, and 0.69 (95% CI 0.58-0.80) for monthly users. For CR, the ORs were 0.61 (95% CI 0.47-0.79) for daily users, 0.64 (95% CI 0.47-0.87) for weekly users, and 0.41 (95% CI 0.26-0.65) for monthly users. There was no significant difference between smokers and non-smokers (HR 0.64, 95% CI 0.27-1.5).
There is an inverse, associative relationship between cannabis use and sinonasal disease. This relationship is insufficiently understood, and there remain significant concerns about the impact of cannabis use, especially smoking, on airway pathologies.
随着美国大麻使用量的不断增加，了解娱乐性使用大麻对慢性鼻窦炎（CRS）、过敏性鼻炎（AR）和慢性鼻炎（CR）等鼻窦疾病的影响至关重要。
这项横断面研究利用美国国立卫生研究院（NIH）的“我们所有人”数据库查询患者调查，以评估大麻使用频率（终生未使用、每月使用、每周使用或过去3个月内每天使用）和消费途径（吸烟或非吸烟）。将大麻使用者与从未使用者在人口统计学、医疗就诊频率和保险方面进行匹配。一个严格的逻辑回归模型计算了调查完成后发生AR、CRS或CR的比值比（OR）。Cox回归风险比（HR）比较了消费途径。
25164名大麻使用者与113418名从未使用者相匹配。使用者发生AR、CRS和CR的几率明显低于从未使用者。对于CRS，与从未使用者相比的OR如下：每日使用者为0.64（95%CI 0.53-0.78），每周使用者为0.61（95%CI 0.48-0.77），每月使用者为0.80。对于AR，每日使用者的OR为0.64（95%CI 0.58-0.71），每周使用者为0.62（95%CI 0.54-0.71），每月使用者为0.69（95%CI 0.58-0.80）。对于CR，每日使用者的OR为0.61（95%CI 0.47-0.79），每周使用者为0.64（95%CI 0.47-0.87），每月使用者为0.41（95%CI 0.26-0.65）。吸烟者和非吸烟者之间没有显著差异（HR 0.64，95%CI 0.27-1.5）。
大麻使用与鼻窦疾病之间存在负相关的关联关系。这种关系尚未得到充分理解，对于大麻使用尤其是吸烟对气道病理的影响仍存在重大担忧。
4级。
